Leerink downgraded Regulus (RGLS) to Market Perform from Outperform with a $7 price target after the company agreed to be acquired by Novartis (NVS) for $7 per share in cash and a $7 per share contingent value right.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS: